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Introduction
Thyroid disease and diabetes mellitus (DM) can be 
connected in a pathophysiological aspect [1–2]. These 
relationships have their significance and respective 
consequences related to insulin needs and insulin sen-
sitivity. Unrecognized thyroid dysfunction may impair 
glycaemic control. A link has been established between 
thyroid hormones and the basal mechanisms control-
ling appetite and energy expenditure, and ultimately it 
is associated with changes in insulin sensitivity. Thyroid 
dysfunction is much more common in patients with DM 
[3–5]. The incidence of thyroid disorders in the diabetic 
population is 13.4%, being highest in women with type 
1 diabetes mellitus (31%) and lowest in men with type 2 
diabetes mellitus (6.9%) [1]. According to the data from 
the latest edition of the IDF Diabetes Atlas [6], the global 
prevalence of hyperglycaemia in pregnancy was 15.8%, 
i.e. 20.4 million live births were affected, in 2019. Data 
shows that 83.6% of cases were the result of gestational 
diabetes mellitus (GDM) [1, 3–5].
Both thyroid dysfunction and gestational diabe-
tes could be connected with maternal complications 
like miscarriage, hypertensive disorders (gestational 
hypertension, preeclampsia), abruptio placentae, 
preterm delivery, caesarean section deliveries, and 
birth trauma [7–10]. Perinatal and neonatal mor-
bidities associated with GDM and thyroid dysfunc-
tion include the following: macrosomia, shoulder 
dystocia, respiratory distress syndrome, neonatal 
hypoglycaemia, polycythaemia, hyperbilirubinaemia, 
impaired neurodevelopment of the child, and low 
birth weight [7–10].
The aim of the study was to determine whether 
there are abnormalities in thyroid hormone levels in 
pregnant women with gestational diabetes.
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Abstract 
Introduction: Thyroid dysfunction and gestational diabetes (GDM) are the two most common endocrine disorders that can be observed 
during pregnancy. Thyroid function abnormalities can be associated with insulin resistance (IR) and changes in carbohydrate metabolism. 
In patients with type 1 diabetes, thyroid function is usually evaluated to rule out abnormalities within a second autoimmune disease. 
Patients with type 2 diabetes are tested for thyroid function in view of the associated weight gain, IR, and changes in metabolism. The 
question arises: Should we also look for thyroid dysfunction in patients with gestational diabetes? The aim of the study was to determine 
whether there are abnormalities in thyroid hormone levels in pregnant women with gestational diabetes.
Material and methods: A monocentric, retrospective study of the Dr Shterev Hospital electronic database was performed. We analysed 
the medical records of 662 pregnant women, divided in two groups — 412 with GDM and 250 with normal glucose tolerance, who gave 
birth in the period 2017–2019. Gestational diabetes mellitus in the study group was diagnosed with a 2-h, 75-g oral glucose tolerance test 
(OGTT) using the International Federation of Gynaecology and Obstetrics (FIGO) and American Diabetes Association (ADA) criteria. 
We analysed the mean serum concentrations of thyroid-stimulating hormone (TSH); free thyroxine (FT4), free triiodothyronine (FT3), 
FT3:FT4 ratio, fasting plasma glucose, age and body mass index in both groups. The groups were compared using the Mann-Whitney U-test.
Results: In patients who developed GDM, significantly higher concentrations of TSH (p < 0.0001) and FT3 (p < 0.0001), lower concentra-
tions of FT4 (p < 0.0001), and higher FT3:FT4 ratios (p < 0.0001) were found. 
Conclusion: The results of this pilot retrospective series reveal that high-normal to high concentration of TSH and low-normal to low 
concentration of FT4 as well as high FT3:Ft4 ratio could indicate increased risk of development of GDM. (Endokrynol Pol 2021; 72 (3): 226–231)
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The inclusion criteria were:
 — pregnant women aged between 18–40 years;
 — diagnosis of GDM;
 — history of normal thyroid function before conception;
 — singleton pregnancy;
 — The exclusion criteria were:
 — age < 18 years or > 40 years;
 — pre-existing diabetes (types 1 and 2);
 — pre-existing thyroid dysfunction;
 — multiple pregnancy.
Using the ETA’s trimester-specific reference range for TSH dur-
ing pregnancy, we divided patients in both groups as follows: 
euthyroid (TSH < 2.5 mIU/L); subclinical hypothyroidism 
(TSH > 2.5– < 4.2 mIU/L); hypothyroidism (TSH > 4.2 mIU/L), 
isolated maternal hypothyroxinaemia (IMH); and gestational 
thyrotoxicosis (Tab. 1). The main idea was to have different patient 
groups with different thyroid hormone concentrations for our 
analysis. This was done in order to assess the threshold of TSH 
concentrations at which changes in blood sugar levels could be 
observed. Regarding thyroid autoimmunity status, women were 
considered antibody positive if anti-TPO (thyroid peroxidase) an-
tibodies concentrations were > 35 IU/mL. All patients underwent 
ultrasound of the thyroid gland with assessment of topography, 
size, structure, blood flow, and presence of nodules.
Levothyroxine therapy was initiated in all pregnant women with 
subclinical hypothyroidism and positive anti-TPO (n = 62) and in 
those with hypothyroidism (n = 63). Their thyroid hormones were 
monitored until the end of the pregnancy. In our study women 
with TSH levels > 2.5 mIU/L but < 4.2 mIU/L and without autoim-
munity data were left without therapy. The aim was to evaluate the 
changes in their thyroid hormone concentrations. Their TSH and 
FT4 concentrations were monitored (at least once more before the 
end of the pregnancy). With this step we stopped using the ETA 
guidelines, instead following those of the ATA [14].
Patients with gestational thyrotoxicosis were excluded from the 
analysis.
Statistical analysis
Analysis was performed using Statistical Package for Social Sci-
ences (SPSS) v.20.0. Data were expressed as percentages (num-
bers), means, or medians. Parametric and nonparametric tests for 
differences were used based on the normality of the distribution 
of Kolmogorov-Smirnov and Shapiro-Wilk, as well as for the 
uniformity of Fisher dispersions. The comparison between the 
two groups of patients (GDM group and control group) in terms 
of different indicators was made with the Mann-Whitney U-test. 
Non-metric variables were represented by relative frequencies (in 
percent). The chi-square test was used to compare the difference 
Material and methods
Study design and setting
This was a case-control study comparing two groups of pregnant 
women. For the purpose of the study the electronic database of 
“Dr Shterev Hospital” was used. We retrospectively reviewed the 
data from the electronic medical records of 662 pregnant women 
who had attended in the clinic in the period 2017–2019. Observed 
women were divided into two groups: a GDM group (n = 412) and 
a control group (patients with normal glucose tolerance, n = 250). 
The diagnosis of GDM was made with a 2-h, 75-g oral glucose toler-
ance test (OGTT) using the International Federation of Gynaecology 
and Obstetrics (FIGO) and American Diabetes Association (ADA) 
criteria [11–13]. TSH; FT4, FT3, and anti-TPO concentrations were 
evaluated in all patients at the time of performing the glucose 
challenge test. There is no established national reference range 
for TSH concentrations during pregnancy in Bulgaria. Therefore, 
the recommendations and criteria set out by some of the major 
professional organizations (American Thyroid Association [ATA], 
European Thyroid Association [ETA], Endocrine Society) were used. 
The Bulgarian Society of Endocrinology (BSE) have taken into ac-
count and borrowed the recommendations of ETA, according to 
which a fixed TSH trimester-specific range is used in the absence 
of a population-specific one, such as the following: first trimester 
— 0.1–2.5 mIU/L; second trimester: 0.2–3.0 mIU/L; third trimester: 
0.3–3.0 mIU/L [15–16]. 
Mean serum concentrations of TSH, FT4, FT3, anti-TPO, FT3:FT4 ra-
tio, fasting blood glucose (mmol/L), and body mass index (BMI) 
were compared. The BMI of the patients was calculated on the 
basis of the accepted weigh:height2 ratio. The TSH concentra-
tions were determined by the immunochemiluminescent method 
(Cobas 6000), and the laboratory TSH reference interval for the 
non-pregnant population was 0.27–4.20 mUI/L. FT4 and FT3 con-
centrations were determined by the immunochemiluminescent 
method (Cobas 6000), with the reference interval for the FT4, for the 
non-pregnant population — 12–22 pmol/L, and for FT3 — 3.2–6.8 
pmol/L. Antibodies were determined by electrochemiluminescent 
method ECLIA (Cobas 6000). The FT3:FT4 ratio was derived by 
dividing plasma concentrations of FT3 by FT4. The interassay 
coefficient of variations were < 5% for the thyroid hormones and 
< 13% for the thyroid antibodies.
Due to the fact that Bulgaria is designated as an iodine-sufficient 
country, we conditionally assumed that the tested women were 
not iodine deficient.
In 210 of the women in the case group, the glucose challenge test 
was performed between the 10th and the 13th weeks of gestation due 
to a history of impaired glucose tolerance, obesity, or family history 
of diabetes mellitus. In the rest of the patients in the case group, 
as well as the patients in the control group, universal screening 
between 24–28 weeks of gestation was performed.
Table 1. Comparison of the thyroid status in both groups
















































The relationship between thyroid dysfunction during pregnancy and GDM Vesselina Yanachkova, Zdravko Kamenov
between two percentages. In all tests, p < 0.05 was considered 
statistically significant. We used receiver operating characteristic 
(ROC) curve analysis, giving a level of sensitivity and specificity, 
to evaluate the TSH indicator as a predictor for GDM. It was es-
timated as the area under the curve (AUC) with 95% confidence 
interval (CI). The AUC ranged from 0.5 (no predictive ability) to 
1 (predictive value).
Results
The main characteristics of observed pregnant women 
are presented in Table 2. The data of 662 women who 
met the inclusion and exclusion criteria were included 
in the study. The mean age of women in the GDM 
group was 33.3 (± 4.93) and 32.8 (± 4.28) for the con-
trol group. The mean BMI in GDM group was 26.078 
(± 5.35), while for the control group it was 22.9 (± 
5.81) (p = 0.422). Regarding the method of conception, 
spontaneous pregnancies predominated (p = 0.0006) in 
both groups. In the comparative analysis of the mean 
concentrations of TSH, patients with GDM, regardless 
of the time of its establishment (I, II, or III trimester 
of pregnancy) showed higher concentrations of TSH 
(2.53 ± 1.36) compared with those in the control group 
(2.46 ± 0.80) mIU/L (p < 0.0001). The mean FT4 con-
centrations in the diabetes group were lower — 13.29 
(± 2.62) vs. 14.18 (± 3.12) pmol/L for the control group. 
Regarding the mean concentrations of FT3, patients 
with gestational diabetes mellitus had higher mean 
concentrations of FT3 (4.08 ± 0.78) compared with 
patients in the control group (3.9 ± 0.68) pmol/L. In 
patients with gestational diabetes mellitus there was 
a higher ratio of FT3:FT4 (0.35 ± 0.62 vs. 0.27 ± 0.47) 
for the control group.
Thyroid hormone concentrations were monitored 
in patients with GDM, who had normal TSH and did 
not require thyroxin therapy. It was found that with 
the progress of pregnancy in a large proportion of 
patients (42 women) there was an increase of the TSH 
concentrations above 3 mIU/L, which was a prerequisite 
for the addition of levothyroxine therapy. There was 
a tendency for a decrease in the FT4 concentrations and 
maternal hypothyroxinaemia was observed in almost 
all patients (n = 87). FT3 concentrations in the same 
patient group were higher.
Using ROC curve analysis, the sensitivity and speci-
ficity of TSH, FT4, and FT3 as indicators and diagnostic 
predictors for GDM were evaluated (Fig. 1–3). 
The area under the curve (AUC) of TSH for pre-
diction of GDM was 0.71 (AUC = 0.71, SE = 0.02, 
95% CI: 0.671–0.75). A threshold concentration of 
TSH ≥ 2.58 mUI/L could predict GDM with a sensitivity 
of 43.6% and a specificity of 92.4% (Fig. 1). The AUC of 
FT4 was 0.60 (SE = 0.02, 95% CI: 0.55–0.65) (Fig. 2) and 
of FT3 was 0.56 (SE = 0.02, 95% CI: 0.51–0.60) (Fig. 3). 
The cut-off concentration of FT3 ≥ 4.99 pmol/L could 
exclude GDM with a sensitivity of 14.4% and a specific-
ity of 96.40%. The cut-off concentration of FT4 ≥ 13.2 
pmol/L could exclude GDM with a sensitivity of 55.4 
% and a specificity of 61.80%.
Table 2. Characteristics of observed pregnant women
Characteristics GDM group (n = 412)
Control group 
(n = 250) p value
Mean age [yrs] 33.3 (± 4.93) 32.8 (± 4.28) 0.251 
BMI [kg/cm2] 26.078 (± 5.35) 22.9 (± 5.81) 0.422
Conception method
   Spontaneous 






Fasting plasma glucose [mmol/L] 5.47 (± 0.80) 4.80 (± 0.67) < 0.001
TSH [mIU/L] 2.53 (± 1.36) 2.46 (± 0.80) < 0.001
FT4 [pmol/L] 13.29 (± 2.62) 14.18 (± 3.12) < 0.001
FT3 [pmol/L] 4.08 (± 0.78) 3.9 (± 0.68) < 0.019
FT3:FT4 ratio — mean 0.350 (± 0.62) 0.27 (± 0.47) < 0.001
Anti-TPO antibodies
   Positive (N)





Gestational age at blood collection 
(weeks of gestation) 19 (± 2.5) 24 (± 2.5) < 0.001
*Data presented as mean ± SD or N (%); SD — standard deviation; GDM — gestational diabetes mellitus; BMI — body mass index; ART — artificial conception;  
TSH — thyroid-stimulating hormone; FT4 — free thyroxine; FT3 — free triiodothyronine; TPO — thyroid peroxidase
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The present study will allow the relationship between 
thyroid function and carbohydrate metabolism to be 
understood. Our results confirm that early parallel 
screening for GDM and thyroid dysfunction is crucial in 
order to avoid complications in the course of pregnancy.
It is well known that thyroid hormones play an im-
portant role in glucose metabolism. Therefore, thyroid 
dysfunction has been suggested to play a role in the 
aetiology of GDM. Abnormal thyroid function during 
pregnancy may affect maternal glucose homeosta-
sis. Several mechanisms are involved in this process: 
reduction of the half-life of insulin; and endogenous 
production of thyroid hormones increases the concen-
tration of GLUT-2 on the hepatocyte membrane.
In hyperthyroid state, the half-life of insulin is 
halved. Pro-insulin levels increase by decreasing the 
C-peptide/pro-insulin ratio. Intestinal glucose absorp-
tion, endogenous glucose production, and lipolysis are 
also increased as well as the levels of catecholamines, 
glucagon, and growth hormone, which leads to impaired 
carbohydrate tolerance and insulin resistance [21, 22].
Hypothyroidism is associated with delayed glu-
cose absorption and peripheral glucose assimilation, 
and reduced hepatic glucose production. This results 
in reduced peripheral glucose utilization and insulin 
resistance [21].
The ratio of serum free T3 (FT3) to free T4 (FT4) (FT3/ 
/ FT4 ratio) may reflect the degree of extra-thyroid T4 to 
T3 conversion activity. The FT3/FT4 ratio is constant in 
healthy adults. High or low FT3 / FT4 ratios may affect 
the peripheral activity of thyroid hormones [20, 21].
The increased ratio of FT3: FT4 is associated with 
disorders of metabolic processes: lipid profile, blood 
pressure, insulin resistance. The decrease in FT4 levels is 
determined by increased peripheral deiodinase activity 
and increased peripheral conversion of FT4 to biologi-
cally active FT3. As a result, there is an increased ratio 
of FT3: FT4 [20, 21]. 
Figure 1. The receiver operating characteristic (ROC) curve 
analysis — thyroid-stimulating hormone (TSH). Diagonal 
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Figure 3. The receiver operating characteristic (ROC) curve 
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Figure 2. The receiver operating characteristic (ROC) curve 
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Peripheral deiodinase activity has been shown to be 
dependent on maternal weight - the higher the mater-
nal weight, the greater the activity. This is associated 
with increased conversion of FT4 to active FT3, and fT3 
induces endogenous glucose production. Weight gain 
or obesity during pregnancy leads to increased periph-
eral deiodinase activity. This changes the ratio of free 
thyroid hormones FT3:FT4 in favour of FT3. Changes 
in thyroid hormone levels underlie abnormalities in 
glucose homeostasis due to their effects associated with 
endogenous glucose production and insulin resistance 
[21, 22].
The present case-control study shows that women 
with GDM have higher TSH and higher FT3 concentra-
tions and FT3:FT4 ratio. 
Isolated maternal hypothyroxinaemia was also seen 
with higher frequency (21.12%). It is well known that 
isolated that IMH is characterized by normal TSH and 
low FT4 concentrations. The causes of IMH include 
iodine deficiency, changes in metabolism of the thyroid 
hormones during pregnancy, obesity, and environmen-
tal and angiogenic factors. Studies show that IMH could 
be associated with increased risk of preterm delivery, 
placental abruption, gestational diabetes, and impaired 
neurocognitive development of the child [18].  
The percentage of anti-TPO-positive patients 
was higher in the GDM group — 38.1% vs. control 
group — 12.8%. The percentage of women in need 
of substitution therapy with thyroxin was higher in 
the GDM group — 26.6% compared with the control 
group — 17.2%. Our findings confirmed the results 
from previous prospective studies, which reported 
increased incidence of GDM in women with overt or 
subclinical hypothyroidism as well as isolated maternal 
hypothyroxinaemia [23–29]. It can be argued that there 
is a link between TSH, FT4, and FT3 concentrations 
and carbohydrate metabolism, although none of the 
conducted studies can ascertain whether changes in 
thyroid hormone levels lead to carbohydrate disorders 
[23–29]. 
Conclusion
The present study clearly shows that patients with 
GDM often have abnormalities in thyroid hormone 
status. This raises the question of the need for early 
universal screening for GDM and thyroid dysfunction 
in all pregnant women. Early parallel screening for 
carbohydrate and thyroid disorders in the first trimester 
of pregnancy would help to obtain an early diagnosis 
of GDM and/or thyroid dysfunction. Additional stud-
ies and analyses are needed to determine which of the 
two disorders is major, but it is appropriate to look for 
abnormalities in carbohydrate metabolism in patients 
with thyroid dysfunction as well as to look for abnor-
malities in thyroid hormone levels in patients with 
dysglycaemia. The results of these pilot retrospective 
series reveal that high-normal to high concentrations of 
TSH and FT3 as well as high FT3:FT4 ratio could indicate 
increased risk of development of GDM.
Conflict of interest 
All authors have contributed sufficiently to the project 
to be included as authors, and all those who are quali-
fied to be authors are listed in the author by line. To the 
best of our knowledge, no conflict of interest, financial 
or other, exists.
Funding
This research did not receive any specific grant 
from funding agencies in the public, commercial, or 
not-for-profit sectors.
References
1. Hage M, Zantout MS, Azar ST. Thyroid disorders and diabetes melli-
tus. J Thyroid Res. 2011; 2011: 439463, doi: 10.4061/2011/439463, indexed 
in Pubmed: 21785689.
2. Stohl HE, Ouzounian J, Rick AM, et al. Thyroid disease and gestational 
diabetes mellitus (GDM): is there a connection? J Matern Fetal Neonatal 
Med. 2013; 26(11): 1139–1142, doi: 10.3109/14767058.2013.773309, indexed 
in Pubmed: 23461673.
3. Perros P, McCrimmon RJ, Shaw G, et al. Frequency of thyroid dysfunc-
tion in diabetic patients: value of annual screening. Diabet Med. 1995; 
12(7): 622–627, doi:  10.1111/j.1464-5491.1995.tb00553.x, indexed in 
Pubmed: 7554786.
4. Gray RS, Borsey DQ, Seth J, et al. Prevalence of subclinical thyroid failure 
in insulin-dependent diabetes. J Clin Endocrinol Metab. 1980; 50(6): 
1034–1037, doi: 10.1210/jcem-50-6-1034, indexed in Pubmed: 7372784.
5. Chubb SAP, Davis WA, Inman Z, et al. Prevalence and progression of sub-
clinical hypothyroidism in women with type 2 diabetes: the Fremantle 
Diabetes Study. Clin Endocrinol (Oxf). 2005; 62(4): 480–486, doi: 10.111
1/j.1365-2265.2005.02246.x, indexed in Pubmed: 15807880.
6. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Interna-
tional Diabetes Federation, Brussels 2019.
7. Bodmer-Roy S, Morin L, Cousineau J, et al. Pregnancy outcomes 
in women with and without gestational diabetes mellitus accord-
ing to the International Association of the Diabetes and Preg-
nancy Study Groups criteria. Obstet Gynecol. 2012; 120(4): 746–752, 
doi: 10.1097/AOG.0b013e31826994ec, indexed in Pubmed: 22996090.
8. Lee KW, Ching SM, Ramachandran V, et al. Prevalence and risk 
factors of gestational diabetes mellitus in Asia: a systematic review 
and meta-analysis. BMC Pregnancy Childbirth. 2018; 18(1): 494, 
doi: 10.1186/s12884-018-2131-4, indexed in Pubmed: 30547769.
9. Svare JA, Hansen BB, Mølsted-Pedersen L. Perinatal complications in 
women with gestational diabetes mellitus. Acta Obstet Gynecol Scand. 
2001; 80(10): 899–904, doi:  10.1034/j.1600-0412.2001.801006.x, indexed 
in Pubmed: 11580734.
10. Rosario PW, Carvalho M, Calsolari MR. TSH reference values in the 
first trimester of gestation and correlation between maternal TSH and 
obstetric and neonatal outcomes: a prospective Brazilian study. Arch 
Endocrinol Metab. 2016; 60(4): 314–318, doi: 10.1590/2359-39970000001
32, indexed in Pubmed: 26886091.
11. American Diabetes Association. 2. Classification and Diagnosis of Dia-
betes: Standards of Medical Care in Diabetes—2020. Diab Care. 2019; 
43(Suppl 1): S14–S31, doi: 10.2337/dc20-s002.
12. Bulgarian Society of Endocrinology. Recommendations for good clini-
cal practice for Diabetes Mellitus [In Bulgarian]. Bulgarian Society of 
Endocrinology, Sofia 2019.
13. Hod M, Kapur A, Sacks D, et al. The International Federation of Gynecol-
ogy and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: 
A pragmatic guide for diagnosis, management, and care#. Int J Gynaecol 
Obstet. 2015; 131: S173–S211, doi: 10.1016/s0020-7292(15)30033-3, indexed 
in Pubmed: 26433807.
14. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the 
American Thyroid Association for the Diagnosis and Management 
231










of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 
2017; 27(3): 315–389, doi:  10.1089/thy.2016.0457, indexed in Pubmed:
28056690.
15. Bulgarian Society of Endocrinology. Recommendations for good clinical 
practice for thyroid disease [in Bulgarian]. Bulgarian Society of Endo-
crinology, Sofia 2019.
16. De Groot L, Abalovich M, Alexander EK, et al. Management of thy-
roid dysfunction during pregnancy and postpartum: an Endocrine 
Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 
97(8): 2543–2565, doi:  10.1210/jc.2011-2803, indexed in Pubmed:
22869843.
17. Lazarus J, Brown R, Daumerie C, et al. 2014 European Thyroid As-
sociation Guidelines for the Management of Subclinical Hypothyroid-
ism in Pregnancy and in Children. Eur Thyroid J . 2014; 3(2): 76–94, 
doi: 10.1159/000362597, indexed in Pubmed: 25114871.
18. Korevaar TIM, Medici M, Visser TJ, et al. Thyroid disease in pregnancy: 
new insights in diagnosis and clinical management. Nat Rev Endo-
crinol. 2017; 13(10): 610–622, doi: 10.1038/nrendo.2017.93, indexed in 
Pubmed: 28776582.
19. Ray S, Gosh S. Thyroid Disorders and Diabetes Mellitus: Double Trouble. 
J Diab Res Ther. 2016; 2(1), doi: 10.16966/2380-5544.113.
20. Männistö T, Vääräsmäki M, Pouta A, et al. Thyroid dysfunction and 
autoantibodies during pregnancy as predictive factors of pregnancy 
complications and maternal morbidity in later life. J Clin Endocrinol 
Metab. 2010; 95(3): 1084–1094, doi:  10.1210/jc.2009-1904, indexed in 
Pubmed: 20080846.
21. Rawal S, Tsai MY, Hinkle SN, et al. A Longitudinal Study of Thyroid 
Markers Across Pregnancy and the Risk of Gestational Diabetes. J Clin 
Endocrinol Metab. 2018; 103(7): 2447–2456, doi: 10.1210/jc.2017-02442, 
indexed in Pubmed: 29889229.
22. Oguz A, Tuzun D, Sahin M, et al. Frequency of isolated maternal hypo-
thyroxinemia in women with gestational diabetes mellitus in a moder-
ately iodine-deficient area. Gynecol Endocrinol. 2015; 31(10): 792–795, 
doi: 10.3109/09513590.2015.1054801, indexed in Pubmed: 26190538.
23. Yang Y, Li Q, Wang Q, et al. Thyroid antibodies and gestational 
diabetes mellitus: a meta-analysis. Fertil Steril. 2015; 104(3): 665–71.
e3, doi: 10.1016/j.fertnstert.2015.06.003, indexed in Pubmed: 26151621.
24. Agarwal MM, Dhatt GS, Punnose J, et al. Thyroid function abnormali-
ties and antithyroid antibody prevalence in pregnant women at high 
risk for gestational diabetes mellitus. Gynecol Endocrinol. 2006; 22(5): 
261–266, doi: 10.1080/09513590600630470, indexed in Pubmed: 16785147.
25. Gong LL, Liu He, Liu LH. Relationship between hypothyroidism and 
the incidence of gestational diabetes: A meta-analysis. Taiwan J Obstet 
Gynecol. 2016; 55(2): 171–175, doi:  10.1016/j.tjog.2016.02.004, indexed 
in Pubmed: 27125397.
26. Maleki N, Tavosi Z. Evaluation of thyroid dysfunction and autoimmunity 
in gestational diabetes mellitus and its relationship with postpartum 
thyroiditis. Diabet Med. 2015; 32(2): 206–212, doi: 10.1111/dme.12580, 
indexed in Pubmed: 25186500.
27. Iranparvar M, Ghorbani H, Azami A, et al. Thyroid dysfunction 
and autoimmunity in pregnant women with gestational diabetes 
mellitus: a cross-sectional study. Int J Adv Med. 2015: 350–353, 
doi: 10.18203/2349-3933.ijam20151007.
28. Velkoska Nakova V, Krstevska B, Dimitrovski Ch, et al. Prevalence of 
thyroid dysfunction and autoimmunity in pregnant women with ges-
tational diabetes and diabetes type 1. Prilozi. 2010; 31(2): 51–59, indexed 
in Pubmed: 21258277.
29. Vafaeimanesh J, Asgarani F, Bagherzadeh M, et al. Thyroid function 
in pregnant women with gestational diabetes: Is screening necessary? 
Thyroid Res Pract. 2015; 12(1): 3, doi: 10.4103/0973-0354.147271.
